Guardant Health, Inc. (GH): Price and Financial Metrics

Guardant Health, Inc. (GH): $31.51

0.33 (-1.04%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

GH Price/Volume Stats

Current price $31.51 52-week high $41.06
Prev. close $31.84 52-week low $15.81
Day low $30.93 Volume 1,123,614
Day high $32.06 Avg. volume 2,089,564
50-day MA $22.14 Dividend yield N/A
200-day MA $24.36 Market Cap 3.86B

GH Stock Price Chart Interactive Chart >


Guardant Health, Inc. (GH) Company Bio


Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was founded in 2011 and is based in Redwood City, California.


GH Latest News Stream


Event/Time News Detail
Loading, please wait...

GH Latest Social Stream


Loading social stream, please wait...

View Full GH Social Stream

Latest GH News From Around the Web

Below are the latest news stories about GUARDANT HEALTH INC that investors may wish to consider to help them evaluate GH as an investment opportunity.

Guardant Health (NASDAQ:GH) shareholders have endured a 78% loss from investing in the stock three years ago

Guardant Health, Inc. ( NASDAQ:GH ) shareholders should be happy to see the share price up 13% in the last month. But...

Yahoo | December 28, 2023

Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford

PALO ALTO, Calif., December 21, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages for the sale of 3,387,446 shares of its common stock in a registered direct offering at an offering price of $26.77 per share.

Yahoo | December 21, 2023

Blood-Based Colorectal Cancer CRC Screening Market Likely to Benefit From FDA's Panel Surprise Advisory Possibility: Analyst

Tuesday, Guardant Health Inc (NASDAQ: GH) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval application (PMA) for its Shield blood test to screen for colorectal cancer on March 28, 2024. Guardant Health submitted the final module of its PMA for Shield on March 10, 2023. The submission includes data from the ECLIPSE study, an over 20,000-patient registrational study evaluating the perf

Yahoo | December 20, 2023

Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

PALO ALTO, Calif., December 20, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.

Yahoo | December 20, 2023

Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test

PALO ALTO, Calif., December 19, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval application (PMA) for the company’s Shield™ blood test to screen for colorectal cancer on March 28, 2024. The date and details of the meeting are subject to confirmation by the FDA and publ

Yahoo | December 19, 2023

Read More 'GH' Stories Here

GH Price Returns

1-mo 27.42%
3-mo 77.62%
6-mo 11.78%
1-year -17.09%
3-year -74.54%
5-year -64.52%
YTD 16.49%
2023 -0.55%
2022 -72.81%
2021 -22.39%
2020 64.93%
2019 107.87%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!